1. Generics Bulletin
  2. >>Products

Another US Humira Biosimilar Approved As Formularies Offer Access

While Alvotech And Stada Broaden Reach Of Higher-Strength Adalimumab In Europe

 
• By Dave Wallace

As Fresenius Kabi receives US FDA approval for its Idacio rival to Humira, positive developments are being seen in terms of adding adalimumab biosimilars to local formularies. Meanwhile, in Europe Stada and Alvotech have broadened access to their Hukyndra high-concentration version.

Fresenius Kabi logo on building
Fresenius Kabi has received US approval for its Idacio biosimilar • Source: Shutterstock

The latest approval for a Humira (adalimumab) biosimilar has been issued by the US Food and Drug Administration, this time for Fresenius Kabi’s Idacio (adalimumab-aacf) version of the top-selling biologic that is due to face US competition in 2023.

Fresenius said that Idacio – a citrate-free 40mg/0

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin